Dupixent Lymphoma Information for Virginia Residents

New Research Links Dupixent to CTCL

Dupixent (dupilumab) is often prescribed to patients in Virginia for chronic inflammatory conditions such as atopic dermatitis, asthma, and chronic sinusitis. Many people in Virginia have found relief using the medication, particularly when other treatments have not worked. However, research and patient reports have raised concerns that Dupixent may be linked to cases of Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare cancer that affects certain immune cells and appears first on the skin. Because early CTCL looks very similar to eczema, it can be difficult to diagnose, and some individuals may be prescribed Dupixent before the lymphoma is identified.

CTCL can develop slowly over years, and in early stages it may appear as itchy, scaly, or irritated skin patches. These symptoms are nearly identical to those of eczema, which is one of the main conditions Dupixent is used to treat. Because of this overlap, some Virginia patients who start Dupixent for eczema may in fact have early CTCL without knowing it. When Dupixent reduces inflammation, symptoms may appear to improve temporarily. This can give the impression that the treatment is working, even though cancer cells may continue to spread. This page provides Virginia residents with a comprehensive look at what medical researchers know about the Dupixent lymphoma link.

Reports Linking Dupixent and CTCL Diagnosis

Several published case reports have described situations where a patient began Dupixent for what was believed to be eczema and was later found to have CTCL. In many of these cases, doctors noted that symptoms changed in ways that did not match typical eczema. Patches may have become thicker, more raised, or more widespread. Itching may have worsened even as redness decreased. In some situations, new nodules or lumps formed in areas that had been treated before.

In some cases, discontinuing Dupixent did not stop the progression of CTCL, suggesting the lymphoma was present before the medication was started. However, the timing and pattern of progression led researchers to question whether Dupixent made the disease more difficult to detect earlier, or whether the medication may have affected how quickly cancer cells multiplied.

Some specialists use the term "unmasking" to describe this effect. The idea is that Dupixent may help reduce inflammation connected to eczema but does not stop the growth of cancerous T-cells beneath the skin. As a result, the underlying disease may go unnoticed for a longer period of time. Early identification is important because CTCL can be easier to manage when treated before it becomes advanced.

Why CTCL Can Be Confused With Eczema

CTCL is challenging to diagnose because the symptoms can look nearly identical to common skin conditions. Both eczema and CTCL can cause:

• Patches of dry or scaly skin
• Redness or discoloration
• Itching that may come and go
• Thickened or rough areas of skin

However, CTCL is caused by cancerous immune cells gathering in the skin, while eczema involves inflammation caused by irritation or allergic reaction. If your doctor in Virginia is concerned, a biopsy may be required to tell the difference. Even then, in very early stages, CTCL can be difficult to detect under the microscope. Because of this, patients who have continued or changing symptoms may need multiple biopsies before CTCL is confirmed.

Dupixent reduces inflammation, which means that early CTCL symptoms may appear milder at first. This can delay the decision to perform a biopsy. Delayed diagnosis may allow CTCL to progress to a more serious stage, which can increase the need for more intensive treatments.

Signs and Symptoms of CTCL from Dupixent

People in Virginia using Dupixent should watch for certain changes and speak to their doctor if they occur. These may include:

• Skin patches that keep spreading or changing shape
• Areas of skin that become thicker or firmer over time
• Lumps, bumps, or nodules under or on the skin
• Itching that gets worse even when skin looks better
• Hair loss in areas where patches develop
• Swollen lymph nodes in the neck, underarms, or groin

These symptoms do not mean someone in Virginia definitely has CTCL. But they do mean that a closer medical evaluation may be important. A dermatologist or oncologist in Virginia who has experience with CTCL can examine symptoms, order tests, and perform a biopsy if needed.

Dupixent Warnings and Monitoring

Drug manufacturers are required to study medications and share known risks with doctors and patients. Critics in Virginia say that Dupixent's manufacturer did not give clear enough warnings about the chance of misdiagnosis, delayed diagnosis, or disease progression in patients who may already have early CTCL. Without clear guidance, Virginia doctors may have believed that symptom changes were simply part of eczema rather than signs of a deeper problem.

Early diagnosis matters because treatment for CTCL can vary depending on the stage of the disease. When CTCL is caught early, treatment may involve topical therapies, light-based treatments, or low-dose medication. When diagnosis is delayed and the disease progresses, more aggressive systemic treatments may be required.

Who May Qualify to File a Dupixent Lymphoma Lawsuit in Virginia?

A resident of Virginia may be eligible to file a claim if they:

• Used Dupixent for eczema, dermatitis, asthma, or sinus issues
• Were later diagnosed with CTCL, Mycosis Fungoides, or Sezary Syndrome
• Experienced delayed diagnosis or symptom progression while using Dupixent

Family membersof Virginia residents may also have the right to file a claim in cases involving severe illness or death.

Dupixent Lymphoma Lawsuits for Virginia Residents

Our firm handles Dupixent lymphoma cases on behalf of Virginia residents on a contingency fee basis. This means there are no legal fees unless we recover compensation for you. We also provide free and confidential case evaluations to help you understand your options.

If you or someone you love in Virginia developed CTCL after using Dupixent, you can contact us to learn about your legal rights and next steps.